12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 8,888,888 | $172,177,761 | 2.51% | |
| 2. | Slate Path Capital David Greenspan | 4,885,000 | $94,622,450 | +19% | 1.45% |
| 3. | Citadel Investment Group Ken Griffin | 1,177,577 | $22,809,667 | +25% | 0% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 865,794 | $16,770,430 | +6% | 0.14% |
| 5. | Aquilo Capital Management Marc Schneidman | 795,813 | $15,414,898 | -13% | 11.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 500 | Director | 36,080 | 2024-04-18 | Filing | |
| $25.00 | 500 | Director | 35,580 | 2024-04-10 | Filing | |
| $27.34 | 150 | Director | 35,080 | 2024-04-02 | Filing | |
| $27.50 | 850 | Director | 34,930 | 2024-03-26 | Filing | |
| $28.00 | 400 | Director | 34,080 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.28 | 9,394 | Officer | 127,107 | 2024-07-02 | Filing | |
| $23.31 | 1,799 | Director | 30,205 | 2024-05-02 | Filing | |
| $28.03 | 6,000 | Officer | 204,851 | 2024-04-01 | Filing | |
| $35.19 | 40,000 | Officer | 400,600 | 2024-03-06 | Filing | |
| $32.71 | 19,730 | Officer, Director | 3,715,048 | 2024-01-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,303,757 | $407,094,965 | 0.01% | |
| 2. | 10,672,076 | $326,565,525 | 0% | |
| 3. | 6,825,111 | $208,848,397 | 0.01% | |
| 4. | 3,371,268 | $103,160,815 | 0% | |
| 5. | 2,751,048 | $84,182,068 | 0% |
News See All
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript August 8, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.78.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.